Organogenesis Holdings (ORGO) Cash & Current Investments (2015 - 2026)

Organogenesis Holdings' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $92.1 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 16.68% year-over-year to $92.1 million in Q1 2026; TTM through Mar 2026 was $92.1 million, a 16.68% decrease from a year earlier, with the FY2025 full-year figure at $94.3 million, down 30.72% from the prior year.
• Cash & Current Investments slipped to $92.1 million in Q1 2026 per ORGO's latest filing, from $94.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $136.2 million in Q4 2024 and bottomed at $64.4 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $94.9 million (2024), against an average of $97.7 million.
• Across the five-year window, Cash & Current Investments soared 22080.9% in 2022 and sank 32.19% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $103.3 million in 2022, then climbed by 1.01% to $104.3 million in 2023, then jumped by 30.49% to $136.2 million in 2024, then slumped by 30.72% to $94.3 million in 2025, then dropped by 2.37% to $92.1 million in 2026.
• Per Business Quant, the three latest ORGO Cash & Current Investments figures stand at $92.1 million (Q1 2026), $94.3 million (Q4 2025), and $64.4 million (Q3 2025).